Orexa
Orexa is a clinical-stage pharmaceutical company that develops and commercializes therapeutics to increase food intake. Its lead compound is a proprietary oral formulation for human use, based on a well known anesthetic. The company is in preparation for phase 2a studies in Post-Operative Ileus and Cachexia, two indications whereby increased food intake could lead to an improved patient health, a shorter hospital stay and significant cost savings. Orexa was founded in 2016 and is headquartered in Herpen (Oss Region, Noord Brabant), The Netherlands.
Team:
Sake Stevenhaagen
CEO / CFO
Investor
Actuarial Sciences (University of Amsterdam)
Former:
Early investor in AM-Pharma.
CFO of Alloksys Life Sciences
Venture Partner of NextStage Early Stage Fund
Ard Peeters
CSO / Founder of Orexa
Biologist
PhD in Psychology
Professor in Behavioural Pharmacology (Radboud UMC, Nijmegen)
Former:
Organon, Schering Plough, MSD
Within Organon Ard was responsible for the development of brain active (CNS) drugs.
Geeske In ‘t Velt 海思柯
Business Development China
MA Chinese Studies & International Management (Leiden University)
Extensive experience in China related business development, with a focus on Life Sciences.
“We have found a very strong signal in our pre-clinical research and successfully completed a Phase 1 study.
Now we are in the most exciting stage: will our mechanism of action also work in patients in Phase 2 ?”
Prof. Dr. Ard Peeters
CS0 and founder of Orexa
Developing a medicine that increases food intake.
